Bispecifics vs. CAR-T in Multiple Myeloma: How to Choose & Sequence

Foreword: Key Takeaways

"My myeloma has progressed on lenalidomide—my oncologist says I qualify for both BCMA CAR T-cell therapy and a bispecific antibody. Which one is better for me?" "Bispecifics can be started tomorrow, whereas CAR-T takes 6 weeks to manufacture—can my disease wait?" "If I start a bispecific antibody now, can I still get CAR-T later?"

As T-cell redirecting therapies (TCRTs) move rapidly from late-line salvage into first relapse (Line 2), choosing between Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies (BsAbs / T-Cell Engagers, TCEs) has become one of the most consequential decisions in modern myeloma care. Based on 2026 international consensus guidelines, three foundational principles guide this choice:

1. "One-and-Done" Cellular Living Drug vs. "Off-the-Shelf" Continuous Therapy: CAR T-cell therapy is a single autologous infusion that delivers deep minimal residual disease (MRD) clearance followed by a multi-year Treatment-Free Interval (TFI)—freeing patients from ongoing clinic visits and chemotherapy. Bispecific antibodies are immediately available "off-the-shelf" therapies that require zero manufacturing wait time and no lymphodepleting chemotherapy, making them indispensable for rapidly progressing relapses, frail or elderly patients, and individuals with severe renal impairment.
2. Whenever Feasible, Sequence CAR-T Before Bispecific Antibodies: Continuous bispecific antibody exposure chronically stimulates endogenous T-cells, driving T-cell exhaustion and reducing the expansion of subsequent CAR-T products. Multi-center real-world data demonstrate that patients treated with CAR-T followed by a bispecific antibody achieve a 5-year Overall Survival (OS) rate of 57.1% (median OS Not Reached), compared to 25.5% (median OS 3.6 years) when a bispecific antibody is given before CAR-T.
3. Both Modalities Work Synergistically When Sequenced with Target Switching: Relapsing after BCMA CAR-T does not exhaust immunotherapy options. Transitioning to a non-BCMA bispecific antibody—such as the GPRC5D-directed Talquetamab (71%–79% ORR, 13.0-month median PFS post-CAR-T) or the FcRH5-directed Cevostamab (17.4-month median duration of response)—or combining Talquetamab + Teclistamab (79% ORR in soft-tissue extramedullary disease) restores durable disease control.

1. Mechanism & Logistics Comparison: "Bespoke Living Soldiers" vs. "Off-the-Shelf Molecular Bridges"

Although both CAR T-cells and bispecific antibodies harness the patient's own T-lymphocytes to perforin-lyse myeloma cells, their engineering, treatment timelines, and day-to-day lifestyle impacts differ fundamentally:

Comprehensive Operational & Lifestyle Comparison

Key Literature & Guidelines: NCCN Guidelines Multiple Myeloma Version 2.2027 (MYEL-G, MYEL-H); Mayo Clinic mSMART Consensus Guidelines v4 (Aug 2026); IMWG Immunotherapy Committee Consensus Guidelines on CAR T-Cell and Bispecific Antibodies (Lancet Oncol 2024/2025).

2. Efficacy & Survival Benchmarks: Early Relapse vs. Late-Line Refractory Disease

When evaluating efficacy, clinicians examine not only the Overall Response Rate (ORR), but also the depth of Complete Response (≥ CR), Minimal Residual Disease (MRD) negativity (10⁻⁵ to 10⁻⁶), Progression-Free Survival (PFS), and Overall Survival (OS).

2.1 Early Relapse (1 to 3 Prior Lines of Therapy, Lenalidomide-Refractory)

Three landmark Phase 3 randomized controlled trials define the early-relapse landscape, prompting major updates in NCCN Guidelines Version 2.2027 (MYEL-H 4 of 5 Erratum) and the ASCO Living Guideline (v2026.1.1):

1. Ciltacabtagene Autoleucel (Cilta-cel — CARTITUDE-4 Phase 3 Trial) — The Sole Category 1 "Preferred" CAR-T in Early Relapse:

   • Study Design: Single infusion of cilta-cel vs. standard-of-care (SoC) triplets (PVd or DPd) in lenalidomide-refractory patients after 1–3 prior lines (including a proteasome inhibitor and an IMiD).
   • Depth of Response: ORR reached 84.6%–86.0% with a ≥ CR rate of 73.1%–77.0% (vs. 21.8%–24.0% SoC). Bone marrow 10⁻⁵ MRD negativity was 60.6% in the intention-to-treat (ITT) population and 88.0% in MRD-evaluable patients (vs. 33.0% SoC).
   • Survival Superiority: At 33.6 months median follow-up, median PFS was Not Reached vs. 11.8 months (HR = 0.29 [initial analysis HR = 0.26], a 71%–74% reduction in progression or death). In the 1 prior line (first relapse) subgroup (n=136), risk of progression or death dropped by 73% (PFS HR = 0.27). Crucially, cilta-cel achieved a statistically significant Overall Survival advantage (30-month OS 76.4% vs. 63.8%; HR = 0.55, P = 0.0009).
2. Teclistamab + Daratumumab (Tec-Dara — MajesTEC-3 Phase 3 Trial) — Co-Preferred Bispecific Combination at First Relapse:

   • Study Design: BCMA × CD3 bispecific antibody teclistamab combined with anti-CD38 daratumumab vs. DPd or DVd in patients with 1–3 prior lines (N=587).
   • Depth of Response: Achieved an ORR of 89.0%, a ≥ CR rate of 82.0%, and a 10⁻⁵ MRD-negativity rate of 58.0%.
   • Survival Superiority: At 34.5 months median follow-up, 36-month PFS was 83.4% and 36-month OS was 83.3% vs. 65.0%, representing an extraordinary 83% reduction in the risk of disease progression or death (HR = 0.17, 95% CI: 0.12–0.23, P < 0.0001). Based on MajesTEC-3 and CARTITUDE-4, the ASCO 2026 Living Guideline (v2026.1.1) and NCCN v2.2027 co-designate Cilta-cel and Tec-Dara (for patients not refractory to anti-CD38 therapy) as preferred options at first relapse.
3. Idecabtagene Vicleucel (Ide-cel — KarMMa-3 Phase 3 Trial) — Moved from "Preferred" to "Other Recommended" in NCCN v2.2027:

   • Evaluated in triple-class exposed patients after 2–4 prior lines: ORR 71.0% vs. 42.0%, ≥ CR 39.0% vs. 5.0%, and median PFS 13.3 months vs. 4.4 months (HR = 0.49, P < 0.001).
   • Major NCCN Version 2.2027 Update (MYEL-H 4 of 5 Erratum): In NCCN Guidelines Version 2.2027, idecabtagene vicleucel (Category 1) was moved from "Preferred Regimens" to "Other Recommended Regimens" for relapsed/refractory disease after 1–3 prior therapies, solidifying cilta-cel as the sole preferred CAR T-cell product in early relapse.

2.2 Late-Line Triple-Class Refractory Setting (≥ 4 Prior Lines of Therapy)

In heavily pretreated, triple-class refractory patients, single-agent CAR T-cell therapies generally achieve higher initial response rates (96%–100% vs. 61%–74%) and longer treatment-free median PFS (30–35 months vs. 11–17 months) than bispecific antibody monotherapies, while dual-bispecific combinations (RedirecTT-1) achieve parity in high-risk extramedullary disease:

Key Literature & Guidelines: NCCN Guidelines Version 2.2027 Multiple Myeloma (MYEL-H 5 of 6 & 6 of 6); CARTITUDE-1/4 (NEJM / Lancet Oncol); MajesTEC-1/3 (NEJM 2025 / ASH 2025 LBA-6); MagnetisMM-3 (Nat Med); MonumenTAL-1 & RedirecTT-1 (NEJM 2025); CIBMTR Real-World Comparison (N=1,581).

3. Safety & Toxicity Trade-Offs: Front-Loaded Acute Risks vs. Cumulative Chronic Immunosuppression

Patients frequently ask which therapy is "safer." Clinically, CAR T-cell therapy concentrates its toxicity within the first 1 to 3 months ("front-loaded acute storm") followed by immune recovery during the treatment-free interval, whereas bispecific antibodies have a milder initial week but accumulate chronic infection or epithelial toxicities during continuous long-term dosing.

4 Critical Safety Distinctions

1. Cytokine Release Syndrome (CRS) & Acute ICANS:

   • CAR-T: CRS occurs in 76%–95% of recipients (median onset Day 1 for ide-cel, Day 7 for cilta-cel; Grade ≥ 3 in 1.0%–5.5%). ICANS occurs in 4.5%–38.7% (Grade ≥ 3 in 2%–5%).
   • Bispecific Antibodies (New NCCN v2.2027 Prophylactic Tocilizumab Recommendation): With step-up dosing and premedication, CRS occurs in 58%–74% of patients, but Grade ≥ 3 CRS is < 1%, and ICANS is rare (3%–15%, virtually all Grade 1–2). Furthermore, NCCN Guidelines Version 2.2027 (MYEL-H, Footnote t) added a major clinical update stating that prophylactic tocilizumab may be considered prior to the first dose of bispecific antibodies to substantially reduce CRS incidence and severity. This makes bispecifics markedly safer for older or medically fragile patients during the first month.
2. Delayed Neurotoxicities (Basal Ganglia vs. Cerebellar Pathways):

   • BCMA CAR-T (Cilta-cel): Because low-level BCMA RNA expression exists in the caudate nucleus and striatum of the basal ganglia, rapid massive CAR-T expansion in patients with high baseline tumor burden can trigger delayed Parkinsonism / movement and neurocognitive treatment-emergent adverse events (MNTs) (6.0% in late-line CARTITUDE-1, reduced to 0.6% in early-line CARTITUDE-4, and 2.7% in real-world CIBMTR data) as well as cranial nerve palsies (CNPs, primarily CN VII facial palsy, 2.5%–9.1%). Effective bridging therapy to lower tumor burden prior to infusion and early steroid intervention for Grade ≥ 2 CRS/ICANS virtually eliminate MNTs.
   • GPRC5D Therapies (Talquetamab / GPRC5D CAR-T): Associated with rare cerebellar ataxia, dizziness, and balance disorders, linked to focal GPRC5D expression in the inferior olivary nucleus of the brainstem.
3. Cumulative Severe Infections & Hypogammaglobulinemia (The #1 Long-Term Hazard of BCMA BsAbs):

   • Continuous BCMA Bispecifics (Teclistamab, Elranatamab, Linvoseltamab): Because normal antibody-producing plasma cells also express BCMA, continuous weekly/biweekly BCMA bispecific dosing causes uninterrupted aplasia of normal plasma cells and profound hypogammaglobulinemia (serum IgG < 400 mg/dL). Consequently, Grade ≥ 3 severe infections occur in 45% to 55% of patients (54% in MajesTEC-3).
   • GPRC5D Bispecifics (Talquetamab): Because GPRC5D is heavily overexpressed on malignant myeloma cells compared to normal plasma cells, polyclonal IgG levels recover during therapy, resulting in a 47% lower risk of severe infection compared to BCMA bispecifics (HR = 0.53) and zero COVID-19 deaths in MonumenTAL-1.
   • GPRC5D On-Target, Off-Tumor Epithelial Effects: Because GPRC5D is expressed in keratinized structures (hair follicles, nail beds, palmar-plantar skin) and the filiform papillae of the tongue, continuous Talquetamab causes dysgeusia/taste loss (37%–63%), skin peeling/xerosis (67%–70%), nail dystrophy/onychomadesis (52%–70%), and weight loss (30%–32%). Transitioning to every-4-week (Q4W) dosing upon achieving response resolves or significantly improves taste and skin symptoms. Notably, one-time GPRC5D CAR-T (Arlo-cel) causes only mild, self-limiting Grade 1/2 skin (30%), nail (19%), and oral (32%) events that resolve within weeks without weight loss.
4. Severe Renal Impairment (eGFR < 30 mL/min or Dialysis):

   • CAR-T: Pre-infusion fludarabine is cleared primarily by the kidneys; severe renal insufficiency (eGFR < 30 mL/min) requires complex dose reductions and synchronized hemodialysis to prevent fatal fludarabine neurotoxicity.
   • Bispecific Antibodies: Catabolized into amino acids via endogenous proteolytic pathways with zero renal clearance. Teclistamab, elranatamab, and talquetamab can be administered at full standard doses in patients with severe renal failure or end-stage renal disease on dialysis.

Key Literature & Guidelines: NCCN Guidelines Version 2.2027 Multiple Myeloma (MYEL-H Footnote t & MYEL-K Footnote a); Mayo Clinic mSMART Consensus Guidelines v4 (Aug 2026); IMWG Consensus on Bispecific Antibodies & CAR-T (Lancet Oncol 2024).

4. Clinical Decision Matrix: Which Patients Should Choose CAR-T vs. Bispecifics?

4.1 5 Patient Profiles Where CAR T-Cell Therapy Is Strongly Preferred

1. Early Biochemical Relapse or Indolent Progression (Especially at First Relapse / Line 2): Low baseline tumor burden maximizes CAR-T expansion, delivers an 80.5% 30-month PFS in standard-risk patients (CARTITUDE-4), and minimizes severe CRS and delayed Parkinsonism.
2. Fit Patients (ECOG 0–1) with Adequate Organ & Renal Function (eGFR ≥ 30 mL/min): Able to tolerate 3-day Fludarabine/Cyclophosphamide lymphodepletion and acute hyperinflammatory monitoring.
3. Patients Prioritizing a Prolonged Treatment-Free Interval (TFI): Ideal for working professionals, active retirees, and patients who wish to avoid indefinite weekly/biweekly clinic injections and chronic corticosteroid exposure.
4. Low-to-Intermediate Pre-Apheresis CAR-HEMATOTOX Score: Adequate baseline bone marrow reserve (platelets, hemoglobin, ANC) and controlled baseline inflammation (ferritin, CRP).
5. Patients with Access to a Certified Academic Center and a Reliable 30-Day Caregiver.

4.2 5 Patient Profiles Where Bispecific Antibodies Are Strongly Preferred

1. Fulminant, Rapidly Progressing Clinical Relapse: Patients with doubling light chains, impending pathological fractures, spinal cord compression, or acute organ compromise who require cytoreduction within 48–72 hours.
2. Older, Frail Patients (IMWG Frailty Score ≥ 2) or Significant Cardiopulmonary/Neurologic Comorbidities: Step-up subcutaneous dosing avoids lymphodepleting chemotherapy and carries a < 1% risk of Grade ≥ 3 CRS.
3. Severe Renal Insufficiency (eGFR < 30 mL/min) or Hemodialysis Dependence: Bispecifics require zero renal dose modification.
4. Refractory Soft-Tissue Extramedullary Disease (EMD) or Aggressive Multiple Myeloma: Dual bispecific therapy (Talquetamab + Teclistamab in RedirecTT-1) achieves a 79% ORR without waiting for cell manufacturing and is explicitly listed in NCCN Guidelines Version 2.2027 for both aggressive MM and post-BCMA salvage.
5. Geographic Distance from Academic Centers or Lack of a Dedicated 24/7 Caregiver: Can be administered closer to home in community oncology settings after initial step-up completion.

Key Literature & Guidelines: NCCN Guidelines Version 2.2027 Multiple Myeloma (MYEL-H); ASCO/IMS Living Guideline Update v2026.1.1 (MajesTEC-3 & CARTITUDE-4); European Myeloma Network Review (Lancet Haematol 2025).

5. The Golden Rules of Sequencing: Why "CAR-T First, Bispecific Second" Doubles 5-Year Survival

For patients who are eligible for both modalities, the order in which CAR-T and bispecific antibodies are sequenced profoundly impacts overall survival. The IMWG Immunotherapy Committee and EHA-EMN have established three evidence-based sequencing rules:

Rule 1: Administer CAR T-Cell Therapy Before Bispecific Antibodies Whenever Possible

• The Biological Mechanism (T-Cell Exhaustion): Autologous CAR-T manufacturing depends entirely on the health of the T-cells harvested during leukapheresis. Continuous bispecific antibody therapy forces endogenous T-cells into chronic activation, driving terminal differentiation (TEMRA phenotype), upregulating inhibitory checkpoints (PD-1, TIM-3, LAG-3, TIGIT), and depleting naive/central memory T-cells.
• Clinical Trial & Real-World Evidence:

  • In CARTITUDE-2 Cohort C, when cilta-cel was administered after prior BCMA bispecific antibody or ADC exposure, the ORR dropped to 57% and median PFS plummeted to just 5.3 months (compared to 34.9 months in bispecific-naïve CARTITUDE-1 patients). Similarly, real-world ide-cel administered after prior bispecifics or ADCs yielded a median PFS of only 2.8 to < 4.0 months.
  • Conversely, when CAR-T is given first, the subsequent treatment-free interval allows the patient's T-cell repertoire to recover. If relapse eventually occurs, sequencing to a bispecific antibody (particularly Talquetamab) achieves a 71%–79% ORR and 13.0-month median PFS (vastly outperforming standard triplet chemotherapy after CAR-T, which yields only a 30% ORR and 0% CR).
  • 5-Year Overall Survival Proof: Multi-center real-world survival analyses confirm that CAR-T \rightarrow Bispecific sequencing achieves a 5-year OS of 57.1% (median OS Not Reached) vs. 25.5% (median OS 3.6 years) for Bispecific \rightarrow CAR-T sequencing—regardless of whether the bispecific targeted BCMA or GPRC5D.

Rule 2: Protect T-Cell Fitness Before Apheresis (Washout Periods & Bridging Strategy)

What if a patient requires a bispecific antibody first, or needs urgent disease control while preparing for CAR-T?

Rule 3: Post-BCMA Relapse Sequencing — The New NCCN Version 2.2027 Dedicated Page (MYEL-H 6 of 6)

In NCCN Guidelines Version 2.2027, the panel introduced a dedicated new algorithm page—MYEL-H (6 of 6): Therapy for Relapsed/Refractory Disease After BCMA Therapy—codifying three evidence-based tiers for post-BCMA CAR-T or post-BCMA bispecific progression:

• Tier 1 (Preferred Target-Switching & Dual-Target T-Cell Redirecting Options):

  • Switch to GPRC5D-Directed Talquetamab-tgvs (Monotherapy or Combinations): Bypasses BCMA antigen loss or mutation, achieving a 71%–79% ORR and 13.0-month median PFS post-BCMA CAR-T. NCCN v2.2027 also lists Daratumumab + Talquetamab-tgvs (TRIMM-2, ORR 82%) and Pomalidomide + Talquetamab-tgvs (MonumenTAL-2, ORR 83%), alongside investigational FcRH5-directed Cevostamab (CAMMA-2, median DOR 17.4 months).
  • Dual Bispecific Combination — Talquetamab-tgvs + Teclistamab-cqyv: Listed on MYEL-H (6 of 6) as a high-potency salvage regimen after prior BCMA therapy, particularly for soft-tissue extramedullary disease (EMD, 79% ORR).
• Tier 2 (Sequential Second BCMA-Directed Therapy After a ≥ 6-Month BCMA-Free Interval):

  • MYEL-H (6 of 6) includes Teclistamab-cqyv, a Second BCMA CAR-T (if eligible/available), or Belantamab mafodotin-containing combinations. Crucially, NCCN v2.2027 notes that when sequencing a second BCMA-directed therapy, a BCMA treatment-free interval of ≥ 6 months (ideally >12\text{--}18 months) and confirmed residual BCMA expression are associated with significantly higher response rates.
• Tier 3 (Non-T-Cell-Redirecting Standard Salvage Regimens on MYEL-H 6 of 6):

  • For patients with profound T-cell exhaustion or cytopenias, NCCN v2.2027 recommends Bortezomib / Selinexor / Dexamethasone (SVd), Carfilzomib-containing regimens, Venetoclax / Dexamethasone (± Daratumumab or Proteasome Inhibitor) for t(11;14) myeloma, or salvage Autologous Hematopoietic Cell Transplant (HCT) using cryopreserved stem cells.

Key Literature & Guidelines: NCCN Guidelines Version 2.2027 Multiple Myeloma (MYEL-G 2 of 4 Footnote r & MYEL-H 6 of 6); IMWG Immunotherapy Committee Sequencing Consensus (Leukemia / Lancet Oncol 2025); Real-World Sequencing Survival Study (ASH 2025 / ASCO 2026).

Conclusion: Orchestrating Both Pillars for Maximum Survival

In 2026, CAR T-cell therapy and bispecific antibodies are not competing rivals—they are complementary, sequential engines of long-term survival in multiple myeloma:

• When disease kinetics are controlled and fitness allows, seizing the window at first or early relapse to harvest healthy T-cells and administer autologous CAR T-cell therapy offers the highest probability of deep MRD negativity and years of medication-free living;
• When fulminant progression demands immediate intervention, when frailty or renal failure precludes lymphodepletion, or when myeloma eventually relapses after CAR-T, off-the-shelf bispecific antibodies (across BCMA, GPRC5D, FcRH5, and dual-targeting combinations) provide rapid, high-potency rescue.

By following the evidence-based roadmap—"Refer Early at Biochemical Relapse, Harvest Healthy T-Cells First, Bridge Effectively, Infuse CAR-T, and Switch Targets with Bispecifics Upon Relapse"—patients and their oncology teams can unlock the full survival potential of modern immunotherapy.

This clinical education and decision guide is compiled by the China Myeloma Development Network (CMDN - ChinaMyeloma.org) based on peer-reviewed literature, NCCN Guidelines, and IMWG/EHA-EMN consensus statements. It is intended for educational purposes only and does not constitute formal medical advice. Please consult your treating hematologist or cellular therapy specialist for individualized clinical decision-making.